SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Howe Jolanda

(Last)

(First)

(Middle)

C/O MIRUM PHARMACEUTICALS, INC.

950 TOWER LANE, SUITE 1050

(Street)

FOSTER CITY

94404

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
05/01/2023

3. Issuer Name and Ticker or Trading Symbol
Mirum Pharmaceuticals, Inc. [ MIRM ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	SVP, Global Controller

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	1,769	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Stock Option (right to buy)	⁽¹⁾	03/11/2029	Common Stock	57,900	$2.94	D
Stock Option (right to buy)	⁽²⁾	05/13/2029	Common Stock	50,000	$6.27	D
Stock Option (right to buy)	⁽³⁾	01/09/2030	Common Stock	25,000	$19.24	D
Stock Option (right to buy)	⁽⁴⁾	01/06/2031	Common Stock	25,000	$19.19	D
Stock Option (right to buy)	⁽⁵⁾	01/05/2032	Common Stock	22,500	$15.87	D
Stock Option (right to buy)	⁽⁶⁾	06/30/2032	Common Stock	18,750	$19.98	D
Stock Option (right to buy)	⁽⁷⁾	01/30/2033	Common Stock	21,250	$23.48	D
Restricted Stock Units	⁽⁸⁾	⁽⁸⁾	Common Stock	2,500	⁽⁹⁾	D
Restricted Stock Units	⁽¹⁰⁾	⁽¹⁰⁾	Common Stock	3,125	⁽⁹⁾	D
Restricted Stock Units	⁽¹¹⁾	⁽¹¹⁾	Common Stock	5,315	⁽⁹⁾	D
Performance Restricted Stock Units	⁽¹²⁾	⁽¹²⁾	Common Tcok	1,563	⁽⁹⁾	D

Explanation of Responses:

1. 1/4th of the 62,500 shares originally subject to the option vested one year after February 28, 2019, and the balance of the shares vest in a series of 36 successive equal monthly installments at the end of each month thereafter.

2. 1/4th of the shares vested one year after April 12, 2019 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

3. 1/4th of the shares vested one year after January 10, 2020 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

4. 1/4th of the shares vested one year after January 7, 2021 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

5. 1/4th of the shares vested one year after January 6, 2022 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

6. 1/4th of the shares vest one year after July 1, 2022 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

7. 1/4th of the shares vest one year after January 31, 2023 (the "Vesting Commencement Date) and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date.

8. The restricted stock units vest in a series of three successive equal annual installments beginning January 6, 2023. 1,250 shares vested January 6, 2023 and the remaining 2,500 shares vest ratably on January 6, 2024 and January 6, 2025.

9. Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer).

10. The restricted stock units vest in a series of three successive equal annual installments beginning July 1, 2023.

11. The restricted stock units vest in a series of three successive equal annual installments beginning January 31, 2024.

12. On March 9, 2021, the reporting person was granted performance-based restricted stock units ("PSUs"), which vest upon the satisfaction of certain performance criteria. On September 29, 2021, such performance criteria were met. 1,562 shares subject to the PSUs vested on September 29, 2021, and 1,563 shares vest on June 30, 2023.

Remarks:

	/s/ Judit Ryvkin, Attorney-in-Fact	05/08/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.